Optional callout banner for highlighted news or events

Learn More
Contact Us

Pii Congratulates Skye Bioscience for First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma.

PRESS RELEASE Hunt Valley, MD (January 24, 2023)

About Skye Bioscience

About Pii

Talk to a Pii Scientist

Contact

Like what you read? Share with your network:

crossmenu